Singapore, Nov. 13 -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and GL Rapha, one of the leading South Korean bio-tech companies (including the subsidiary Hankook Korus Pharm) have agreed to produce over 150 million doses per year of the world's first registered vaccine against the novel coronavirus infection - Sputnik V.

The parties intend to commence production in December 2020 and a rollout of the Sputnik V vaccine in January 2021. RDIF and GL Rapha will supply over 150 million doses per year produced in South Korea for global distribution.

The first interim analysis of The Sputnik V vaccine data of Phase III clinical trials in Russia has demonstrated 92% efficacy against coronavirus based on 20 confi...